Compare FOSL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | RNA |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.3M | 222.5M |
| IPO Year | 1994 | 2025 |
| Metric | FOSL | RNA |
|---|---|---|
| Price | $5.24 | $12.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $7.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 896.7K | 114.7K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,004,406,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $1.66 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $11.13 |
| 52 Week High | $6.16 | $73.06 |
| Indicator | FOSL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 52.55 |
| Support Level | $3.70 | $11.95 |
| Resistance Level | $5.75 | $14.05 |
| Average True Range (ATR) | 0.43 | 0.35 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 59.22 | 80.44 |
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.